Cat. No. 5422
Alternative Names: Cabozantinib, BMS 907351
Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)o
Biological ActivityPotent VEGFR inhibitor (IC50 = 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC50 values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo. Antiangiogenic.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
You et al (2012) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71 4758. PMID: 21613405.
Yakes et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol.Cancer Ther. 10 2298. PMID: 21926191.
If you know of a relevant reference for XL 184 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses XL 184 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: XL 184, supplier, Potent, VEGFR, inhibitors, inhibits, HGFR, HGF, receptor, vascular, endothelial, growth, factors, receptor,, tyrosine, kinases, RTKs, c-Met, KIT, FLT4, AXL, FLT3, FLT1, Tie2, apoptosis, metastasis, antiangiogenics, angiogenesis, antitumor, antitumour, Tocris Bioscience, VEGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.